article

Lymphoma triage from H&E using AI for improved clinical management

  • Journal of Clinical Pathology
  • BMJ
Research footprint

At a glance

الاستشهادات
3
المراجع
23
Comments
0
Paper overview

Abstract

AIMS: In routine diagnosis of lymphoma, initial non-specialist triage is carried out when the sample is biopsied to determine if referral to specialised haematopathology services is needed. This places a heavy burden on pathology services, causes delays and often results in over-referral of benign cases. We aimed to develop an automated triage system using artificial intelligence (AI) to enable more accurate and rapid referral of cases, thereby addressing these issues. METHODS: A retrospective dataset of H&E-stained whole slide images (WSI) of lymph nodes was taken from Newcastle University Hospital (302 cases) and Manchester Royal Infirmary Hospital (339 cases) with approximately equal representation of the 3 most prevalent lymphoma subtypes: follicular lymphoma, diffuse large B-cell and classic Hodgkin's lymphoma, as well as reactive controls. A subset (80%) of the data was used for training, a further validation subset (10%) for model selection and a final non-overlapping test subset (10%) for clinical evaluation. RESULTS: AI triage achieved multiclass accuracy of 0.828±0.041 and overall accuracy of 0.932±0.024 when discriminating between reactive and malignant cases. Its ability to detect lymphoma was equivalent to that of two haematopathologists (0.925, 0.950) and higher than a non-specialist pathologist (0.75) repeating the same task. To aid explainability, the AI tool also provides uncertainty estimation and attention heatmaps. CONCLUSIONS: Automated triage using AI holds great promise in contributing to the accurate and timely diagnosis of lymphoma, ultimately benefiting patient care and outcomes.

Record transparency

Publication details

DOI
10.1136/jcp-2023-209186
OpenAlex
W4388541018
Document type
article
Language
EN
Source
Journal of Clinical Pathology
Last metadata update
المجتمع

Comments

تسجيل الدخول للانضمام إلى النقاش.

  1. لا توجد تعليقات بعد. ابدأ النقاش.